Becton, Dickinson and Company (NYSE:BDX) EVP Sells $13,961.20 in Stock

Becton, Dickinson and Company (NYSE:BDX) EVP Michael Feld sold 76 shares of the company’s stock in a transaction dated Monday, September 28th. The stock was sold at an average price of $183.70, for a total transaction of $13,961.20. Following the transaction, the executive vice president owned 19,644 shares in the company, valued at $3,608,602.80. The trade was a 0.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Michael Feld also recently made the following trade(s):

• On Wednesday, August 26th, Michael Feld sold 165 shares of Becton, Dickinson and Company stock. The shares were sold at an average price of $188.49, for a total transaction of $31,100.85.
• On Monday, July 27th, Michael Feld sold 75 shares of Becton, Dickinson and Company stock. The stock was sold at an average price of $157.13, for a total value of $11,784.75.

Becton, Dickinson and Company Stock Performance

NYSE BDX opened at $178.00 on Friday. The business has a 50 day moving average price of $180.28 and a 200 day moving average price of $161.60. The company has a market capitalization of $49.05 billion, a P/E ratio of 53.61, a PEG ratio of 12.62 and a beta of 0.21. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $193.07. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.The company had revenue of $4.98 billion for the quarter, compared to the consensus estimate of $4.89 billion. During the same period in the previous year, the business earned $3.68 earnings per share. Becton, Dickinson and Company’s quarterly revenue was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Sell-side analysts expect that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th were given a dividend of $1.05 per share. The ex-dividend date was Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a yield of 2.4%. Becton, Dickinson and Company’s payout ratio is presently 126.51%.

Analyst Upgrades and Downgrades

BDX has been the subject of a number of recent research reports. Bank of America raised their price objective on shares of Becton, Dickinson and Company from $185.00 to $200.00 and gave the stock a “neutral” rating in a research note on Monday, August 31st. Citigroup reiterated a “buy” rating on shares of Becton, Dickinson and Company in a report on Thursday, August 13th. Wells Fargo & Company raised their price target on Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an “equal weight” rating in a research report on Friday, August 7th. Stifel Nicolaus set a $195.00 price target on Becton, Dickinson and Company in a report on Friday, August 7th. Finally, Piper Sandler increased their price objective on Becton, Dickinson and Company from $161.00 to $175.00 and gave the company a “neutral” rating in a research note on Friday, August 7th. Eight equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $187.67.

Institutional Trading of Becton, Dickinson and Company

Several hedge funds and other institutional investors have recently bought and sold shares of the company. SHP Wealth Management acquired a new stake in shares of Becton, Dickinson and Company during the fourth quarter worth $26,000. Meeder Asset Management Inc. lifted its position in Becton, Dickinson and Company by 152.2% during the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock worth $27,000 after buying an additional 102 shares during the period. Main Street Group LTD purchased a new position in Becton, Dickinson and Company during the first quarter worth about $29,000. Bell Investment Advisors Inc acquired a new stake in Becton, Dickinson and Company in the 2nd quarter worth about $29,000. Finally, Kelleher Financial Advisors purchased a new stake in Becton, Dickinson and Company in the 2nd quarter valued at about $30,000. 86.97% of the stock is owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company, doing business as BD, is a global medical technology company that develops, manufactures and sells devices, diagnostic products and solutions for healthcare providers, researchers and patients. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, the company serves customers in hospitals, laboratories, physician offices, pharmacies and other healthcare settings worldwide.

BD’s Medical segment offers products used for medication delivery and management, including needles, syringes, infusion systems, medication preparation and dispensing technologies, and systems designed to help improve medication safety.